Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

This is a phase 1, open-label, single arm study to evaluate the safety, tolerability and
pharmacokinetics of multiple doses of BHV-0223 in subjects with ALS.

Inclusion Criteria:

1. Subjects with diagnosed ALS by the revised El Escorial diagnostic criteria, including
laboratory supported probable, probable, or definite ALS;

2. Subjects who have never taken riluzole tablets, OR Subjects who previously took
riluzole tablets but discontinued at least 1 month prior to the screening visit.
Subjects must not have had ALT or AST > 5 x ULN while taking riluzole tablets, or any
other clinically significant tolerability issues (e.g., hypersensitivity reactions) in
the judgement of the investigator;

3. Subjects determined by the investigator to be medically stable;

4. Subjects determined by the investigator to be willing and physically able to complete
the study as designed, with or without caregiver assistance.

Exclusion Criteria:

1. Target Disease Exceptions

2. Medical History Exceptions

1. Subject is known to have a current diagnosis of acute or chronic viral hepatitis;

2. Subject is known to have any other acute or chronic liver disease that is
clinically significant in the investigator's judgment;

3. Subject has a history of a clinically significant medical condition that would
interfere with the subject's ability to comply with study instructions, would
place the subject at increased risk, or might confound the interpretation of the
study results in the investigator's judgment;

4. Any other sound medical, psychiatric and/or social reason in the investigator's
judgment;

3. Physical and Laboratory Test Findings

1. Positive urine pregnancy test in WOCBP at screening;

2. Subject has evidence of organ dysfunction or any clinically significant deviation
from normal in physical examination, vital signs, or other determinations beyond
what is consistent with the target population, in the investigator's judgment;

3. Subject has liver function testing abnormalities (ALT, AST , or total bilirubin)
that are > 1 x ULN;

4. Other Exclusions a. Subjects who are unable to be compliant with the visit schedule or
protocol procedures.